AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04567303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zifibancimig
Description: Part 1: multiple ascending doses by IVT injection. Each participant will receive zifibancimig at a constant volume of 50 microliter in the study eye.~Part 2: participants will be randomized to one of two dose levels of zifibancimig in the PD implant.~Part 3: Participants will receive one of the two dose levels of zifibancimig in the PD implant.
Study NCT04567303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Participants will receive ranibizumab 100 mg/mL through the PD implant
Study NCT04567303 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Port Delivery Platform
Description: Participants will receive intraocular refillable device that is surgically inserted into the eye for continuous delivery of drugs into the vitreous.
Study NCT04567303 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Port Delivery Platform
Description: Participants will receive intraocular refillable device that is surgically inserted into the eye for continuous delivery of drugs into the vitreous.
Study NCT00898482 — intervention group
Intervention type: OTHER
Intervention: This is a non-intervention study for all groups.
Description: This is a non-intervention study.
Study NCT00898482 — intervention group
Intervention type: OTHER
Intervention: study of socioeconomic and demographic variables
Description: Non-intervention study.
Study NCT04227405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TOGETHER Workshop
Description: Couples were required to participate in a 20 hour workshop (8 sessions of 2 1/2 hours each)in groups of 3 to 8 couples. These groups were facilitated by a financial expert and a couples' expert. The workshop is interdisciplinary and psycho-educational. Couples learn about skills to improve their communication about stress and money problems, conflict resolution, individual and couple stress management in general and about money stress in particular, and financial management
Study NCT04227405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Employment Support Services
Description: Only for those participants that were in need of employment support services. If the needs assessment conducted by the case manager indicated an employment or career need. After completion of the TOGETHER workshop, an employment case manager met with the participant, conducted an employment needs assessment and connected the participant with a workforce agency or one-stop employment centers. After doing so, the employment case manager followed through the various steps that the participant had to complete as part of the employment services for a period of 6 months
Study NCT04954950 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT04191564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low perfusion state
Description: reduce SAP below 100 mmHg
Study NCT04191564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: normal perfusion state
Description: maintain SAP above 100 mmHg
Study NCT04516850 — intervention group
Intervention type: GENETIC
Intervention: Expression of receptors and activating proteases
Description: Level of expression of the mRNA of the genes encoding ACE2, TMPRSS2, TMPRSS4 and AR along with reference genes (beta-actin and EPCAM) in nasopharyngeal swabs taken from patients tested for COVID-19
Study NCT03460626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lavender Oil
Description: The oil used in this study will be lavender oil with a final concentration of 3% using almond oil (90%) as diluent. The oil after dilution and final preparation will be converted to proper clean vial in a fix amount (10 ml) and given to the students.
Study NCT03460626 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: an odorless oil without any therapeutic effect
Study NCT01142947 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: beclomethasone dipropionate
Description: 160 mcg twice a day (320 mcg per day total)
Study NCT04516850 — intervention group
Intervention type: GENETIC
Intervention: Polymorphism of the HSD3B1
Description: Formalin-fixed paraffin embedded tissue blocks will be amplified using polymerase chain reaction (PCR) based experiments followed by direct sequencing (Sanger sequencing)
Study NCT04554654 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: transvaginal ultrasound,
Description: transvaginal ultrasound performed on day of the start of progesterone supplementation and on the day of frozen embryo transfer; serum progesterone level measurement on day of frozen embryo transfer
Study NCT00358384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib will be available in dosing strengths of 0.1, 0.5 and 1 percent.
Study NCT00358384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pazopanib vehicle
Description: Pazopanib vehicle will be given to subjects.
Study NCT00358384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Betamethasone valerate
Description: Betamethasone valerate ointment with 0.1 percent concentration will be given to subjects.
Study NCT00358384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcipotriol
Description: Calcipotriol ointment with 0.005 percent concentration will be given to subjects.
Study NCT03562442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Description: Smoking cessation with or without professional / medical support
Study NCT01802879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Panobinostat was provided as 5, 10 and 20 mg hard gelatin capsules to be taken orally. Patients started on dose from parent protocol and dose modifications were at the discretion of the investigator based on guidance provided in the protocol and IB.
Study NCT04626999 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Bundle ACL Reconstruction
Description: Arthroscopy Single Bundle ACL Reconstruction is a procedure to reconstruct the ACL using one bundle.~The procedure uses Hamstring (Gracillis muscle and Semitendinosus muscle) as a graft.
Study NCT04626999 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double Bundle ACL Reconstruction
Description: Arthroscopy Double Bundle ACL Reconstruction is a procedure to reconstruct the ACL using Two bundles (Double bundle).~The procedure uses Gracillis tendon as a Posterolateral bundle graft and Semitendinosus tendon as an Anteromedial bundle graft.
Study NCT03936400 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Couple-based intervention and and evaluation of effectiveness in increasing adjustment of sexuality and intimacy
Description: Three face-to-face therapeutic conversations and an optional web-based evidence based information (about sexual consequences of cancer treatment)
Study NCT02407847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: care provided by Nurse Practitioners
Description: Patients will receive care at the Primary Out of Hours Emergency Service by a Nurse Practitioner instead of a General Practitioner (substitution of care from physicians to nurses).
Study NCT01190189 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK580299 (Cervarix)
Description: 3-dose schedule intramuscularly vaccination
Study NCT02927678 — intervention group
Intervention type: OTHER
Intervention: white blood cell SPECT/CT (Single Photon Emission Computed Tomography/Computed Tomography) imaging
Study NCT01380652 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: whole body vibration training
Description: pulmonary rehabilitation with strength and endurance training and additionally vibration training
Study NCT02271217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02271217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dalfampridine-ER 7.5mg
Study NCT02271217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dalfampridine-ER 10mg
Study NCT01572714 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Support Program
Description: The social support program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Topics will include information on MS, disease modifying medications, preventive screening, community organizations, nutrition, cognitive problems, and hiring an aide.
Study NCT01572714 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Program
Description: The physical activity education program will consist of 3 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program.
Study NCT01572714 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Plus Fatigue Management Education Program
Description: The physical activity plus fatigue management education program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program. In addition, subjects in this course will learn strategies to reduce fatigue, such as taking rest breaks and re-arranging workspace.
Study NCT03923270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants in all arms will be administered 1500 mg of Durvalumab intravenously every 4 weeks.
Study NCT03923270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Participants in arm B will be administered 75 mg of Tremelimumab intravenously every 4 weeks for up to 4 doses.
Study NCT03923270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Pill
Description: Participants in arm C will be self-administer 300 mg of Olaparib orally.
Study NCT03923270 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiotherapy
Description: Thoracic Radiotherapy will be administered at 3 Gray units X 10 fractions
Study NCT03923270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Participants in arm D will be administered 300 mg of Tremelimumab intravenously in 1 single dose
Study NCT03900793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan will be administered orally daily on days 1-42 (6 weeks) with dose level assignments per Table 1 of the protocol. Dosing will be performed based on weight in kilograms and rounded to the nearest 12.5 mg (half of 25 mg tablet). Dose level 1 dosing will not exceed 50 mg daily and dose levels 2 and 3 dosing will not exceed 100 mg daily. Doses should be taken at approximately the same time daily and patients should fast for > 4 hours prior to dosing
Study NCT03900793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib will be administered orally daily on days 1-28 (4 weeks), followed by 14-day rest period (2 weeks). Dosing will be performed based on body surface area (BSA) in mg/m2 per Table 1 of the protocol. Doses should be taken at approximately the same time daily.
Study NCT03426579 — intervention group
Intervention type: DEVICE
Intervention: NeuroSENSE ®in children
Description: Before induction of anesthesia NeuroSENSE ® monitoring will be applied to all subjects.General anesthesia with dexmedetomidine and remifentanil is titrated based on the evaluation of respiratory clinical signs (cough, spasm, movement) and immobility of the vocal cords. The anesthesiologist performing anesthesia will be blinded for the Wavelet-based Anesthetic Value for Central Venous System (WAVCNS) index assessed by NeuroSENSE ® and will adjust dexmedetomidine according to clinical signs, which is standard of care. Retrospectively data obtained by NeuroSENSE ® will be compared to evaluate whether they are useful in predicting upcoming unwanted airway reflexes.
Study NCT02800005 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AFA group (successive patients)
Description: The abdominal fat area at the umbilical level was measured using a CT scanner(sango Mount Monitor Wireless Panel; Siemens , Munich, Germany) while the examinee was in a supine position and estimated using a Volume software (fat Pointer; Siemens , Munich, Germany). The imaging conditions were 120 kilovolt and 50 milliampere, using a 5-mm-thick slice.The areas covered by visceral fat software calculated from pixels with densities ranging from-190 to -30 hounsfield unit . No contrast agent is needed.
Study NCT02800005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMI group (successive patients)
Description: The formula for BMI is weight in kilograms divided by height in meters squared (kg/m2). the normal range is usually considered to be 18.5 to 24.9, with less than 18.5 considered underweight, more than 25.0 considered overweight and above 30.0 obese.
Study NCT02800005 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: BMI group (successive patients)
Description: The formula for BMI is weight in kilograms divided by height in meters squared (kg/m2). the normal range is usually considered to be 18.5 to 24.9, with less than 18.5 considered underweight, more than 25.0 considered overweight and above 30.0 obese.
Study NCT01084148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V0034CR01B
Study NCT01084148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: V0034CR01B vehicle
Study NCT02757352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC
Study NCT02757352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT03092570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: With stimulation
Description: ramp stimulation from 0 to 2 mA followed by 20 minutes of stimulation at 2mA while practicing during 3 of the 4 sessions
Study NCT03092570 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: No stimulation
Description: ramp stimulation from 0 to 2 mA followed by 30 sec of stimulation at 2mA.
Study NCT02843815 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryosurgery
Description: Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
Study NCT02843815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
Study NCT02843815 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK Immunotherapy
Description: Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
Study NCT05492747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo Care an Effect
Description: Researchers evaluated vital signs and oxygen saturation of preterm infants in the kangaroo care group 15 minutes before kangaroo care. After the baby's mother was admitted to the NICU, she was assisted by the researcher for hand hygiene and they went to the incubator together. The mother was seated in a comfortable chair next to the incubator. After the researcher covered the head and back of the preterm baby with a baby blanket, she took it from the incubator and placed it between the mother's breasts, with the head up and upright. The baby was supported not only by the neck and shoulders, but also by the whole body. Skin contact between mother and baby was ensured at the highest level. The baby was positioned so that its lips were touching the mother's nipple. The researcher waited until the baby opened its mouth.
Study NCT03565003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-3068
Description: 25 mg,100 mg
Study NCT01237288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-521
Study NCT01225926 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toric T3 - T9
Description: Commercially available, acrylic, multifocal IOL intended to provide visual correction over the lifetime of the cataract patient
Study NCT01225926 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IQ SN60WF
Description: Commercially available, acrylic, monofocal IOL intended to provide visual correction over the lifetime of the cataract patient
Study NCT04481594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPN-01
Description: 25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg HPN-01 capsules
Study NCT04481594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg HPN-01 placebo capsules
Study NCT01013831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO
Study NCT01013831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01013831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03864991 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: e-device for step count (fit-bit)
Description: Patients in this group will receive fitbit device to count their daily steps and record it into their log books.
Study NCT03864991 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: e-messages for log book
Description: Patients in this group will receive e-messages to maintain their log books as per instruction for blood sugar levels and send back weekly through snap shot.
Study NCT03864991 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: e-messages for log book & fit-bit
Description: Patient in this group will receive e-messages to maintain their log books for blood sugar levels as well as use fitbit device and maintain their log book for daily step count and send back weekly through snap shot.
Study NCT03197467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab at fixed dose: 200 mg q3w i.v. for 2 cycles
Study NCT02494895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Description: Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to stop aspirin at 3 months after PCI.
Study NCT02494895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor with Aspirin DAPT(dual antiplatelet treatment)
Description: Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to continue DAPT (aspirin+ticagrelor) up to 1 year.
Study NCT00716768 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Inguinal Hernia Repair
Description: Laparoscopic Inguinal Hernia Repair
Study NCT00716768 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Inguinal Hernia Repair
Description: Open Inguinal Hernia Repair
Study NCT02155309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Study NCT02155309 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03003169 — intervention group
Intervention type: OTHER
Intervention: Medical questionnaire
Description: * quality of life questionnaire (EORTC QLQ-C30 and QLQ-BR23)~* Hospital Anxiety and Depression scale~* satisfaction care questionnaire (IN-PATSAT32)
Study NCT03241576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small portion size provision
Description: The intervention is the small meal size participants are provided with during a lunchtime session in the laboratory.
Study NCT03241576 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Large portion size provision
Description: The intervention is the large meal size participants are provided with during a lunchtime session in the laboratory.
Study NCT00826098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Addition of PRP to total knee replacement procedure
Study NCT00844779 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Gastric bypass.
Study NCT00844779 — intervention group
Intervention type: PROCEDURE
Intervention: cholecystectomy or benign liver tumor removal
Description: cholecystectomy or benign liver tumor removal
Study NCT01427010 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]FDG-PET-voxel intensity-based IMRT
Description: Non-controlled, non-randomized, prospective study on 18F-Fluorodeoxyglucose-Positron Emission Tomography (\[18F\]FDG-PET)-voxel intensity-based intensity-modulated radiotherapy (IMRT) (dose painting) adapted to the anatomical and biological changes as detected by per-treatment FDG-PET/Computertomography (CT) acquired at the end of the 2nd and the 4th week of treatment.